Compare ACFN & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACFN | CLNN |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 57.4M |
| IPO Year | 2006 | 2021 |
| Metric | ACFN | CLNN |
|---|---|---|
| Price | $21.11 | $4.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $33.75 |
| AVG Volume (30 Days) | 58.0K | ★ 104.1K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $4,350,000.00 | $200,000.00 |
| Revenue This Year | N/A | $17.64 |
| Revenue Next Year | N/A | $19,516.77 |
| P/E Ratio | $227.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.42 | $3.48 |
| 52 Week High | $31.88 | $13.50 |
| Indicator | ACFN | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 43.44 |
| Support Level | $16.19 | N/A |
| Resistance Level | $21.32 | $4.70 |
| Average True Range (ATR) | 1.22 | 0.37 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 63.93 | 40.27 |
Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. The company operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.